Digital Health Intervention to Improve Health Care and Outcomes for Breast Cancer Patients

Breast Cancer Clinical Trial

Official title:

Design and Evaluation of the Effectiveness of a Digital Health Intervention to Improve Health Care and Outcomes for Cancer Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05925257
• Other study ID #: R-2021-785-059
• Status: Recruiting
• Phase: Phase 2
• Start date: March 5, 2024
• Est. completion date: March 31, 2025

Study information

• Verified date: April 2024
• Source: Coordinación de Investigación en Salud, Mexico
• Contact: Svetlana V. Doubova, MD. DSc.
• Phone: +525556276900
• Email: svetlana.doubova[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: Nearly 30,000 Mexican women develop breast cancer annually. These patients frequently present multiple unmet supportive care needs. In high-income settings, incorporating electronic patient-reported outcomes (ePROs) into cancer care has demonstrated potential for increasing patient-centred care and reducing unmet needs. No such ePRO interventions have been implemented in Mexico. The objectives of this study are (I) to design a two-component intervention for monitoring ePROs among breast cancer patients using a responsive digital application and proactive follow-up by nurses, (II) to perform intervention pilot testing of the study materials, and (III) to conduct the clinical trial to assess usability and effectiveness of the intervention.

Methods. The investigators designed a two-component intervention for women receiving breast cancer treatment: a responsive web application for monitoring ePROs and clinical algorithms guiding proactive follow-up by nurses. The investigators will conduct a pilot test of the intervention with 50 breast cancer patients for six weeks to assess the feasibility and inform intervention adaptations. After that, the investigators will conduct a parallel arm randomized controlled trial assigning 205 patients each to intervention and control in one of Mexico's largest public oncology hospitals. The intervention will be provided for six months, with additional three months of post-intervention observation. The control group will receive usual healthcare and a list of information sources on relevant breast cancer topics. Women diagnosed with stages I, II, or III breast cancer who initiate chemo and/or radiotherapy will be invited to participate. The study outcomes will include supportive care needs, quality of life, use of emergency services and unscheduled hospitalizations, the usability of the ePRO App, and adherence to the intervention. Information on the outcomes will be obtained through web-based self-administered questionnaires collected at baseline, 1, 3, 6, and 9 months.

Description:

An unblinded, parallel-arm, randomized, controlled clinical trial will be conducted. This phase 2 clinical trial focuses on exploring the effect of the intervention on the study variables.The intervention group will be given access to the ePRO application and proactive clinical care, including study nurses responding to ePROs and weekly health information videos for six months. Participants of the control group will be provided with a list of electronic links to videos on breast cancer-relevant topics on the websites of recognised cancer associations and health institutions. All participants will continue to receive the usual health care provided by the hospital. Study intervention wil last 6 months with additional passive folow-up till 9 months to allow post-intervention monitoring.

The participants will be randomly allocated to the intervention or control groups. The minimization technique with MS-DOS Minim program will be used for randomization. It will be conducted by a research assistant who will use a pre-prepared list of random numbers to randomize the first six participants. Starting with the seventh participant, randomization will be carried out using MS-DOS Minim program. The minimization technique is recommended as a standard to ensure that clinical trial groups are similar in terms of participant characteristics, such as age, schooling, breast cancer stage and treatment modality.

Intervention implementation: The lead researcher will weekly obtain the list of breast cancer patients who have started or will start neoadjuvant or adjuvant treatment with chemotherapy or radiotherapy within two weeks in the oncology hospital. The previously trained nurses will use this list to invite all eligible breast cancer patients to participate in the study. Initially, patients will be invited by telephone calls to attend the hospital or the research unit (located at the same medical center as the oncology hospital) to receive the study-related information and to confirm eligibility. Those who meet the inclusion criteria will be provided with the option to participate and invited to provide informed consent prior to participation. Participants will be provided with a username, password, and access to the intervention or control interface of the responsive ePRO App, and training on its use. All participants will be asked to answer the baseline record of sociodemographic and clinical characteristics and questionnaires to assess study outcomes. Intervention arm participants will be asked to complete the weekly register and will receive weekly WhatsApp reminders. Study nurses will contact patients without two weekly records to encourage adherence to the intervention. Study nurses will be supported by the study oncologist/ oncology resident to ensure adherence to the intervention activities. Additionally, the nurses will be in regular contact with the study team and will record their activities in the corresponding interface of the responsive ePRO App.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 410
• Est. completion date: March 31, 2025
• Est. primary completion date: December 29, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 75 Years

Eligibility

Inclusion Criteria:

• Women

• Age between 20 and 75 years

• Breast cancer stages I, II, or III

• Neoadjuvant or adjuvant treatment with chemotherapy that started within two to six weeks before enrollment

• Access to the internet on mobile phone, computer or tablet

• Written informed consent

Exclusion Criteria:

• Illiterate

• Stage IV breast cancer

• Cognitive dysfunction

• Blindness or low vision not corrected with glasses

• Severe depression (=12 points on the Hospital Anxiety and Depression Scale)

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Other:
• ePRO application and proactive clinical care with nurses.
The investigators defined ePRO intervention as a weekly register of breast cancer patients' symptoms and supportive care needs using the study ePRO App combined with proactive follow-up by nurses guided by predefined clinical algorithms and a weekly cellphone message providing an educational video from a recognised cancer association or health institution. The intervention will be provided for six months with additional three months of post-intervention observation.

Locations

Country	Name	City	State
Mexico	Hospital de Oncología del Centro Médico Nacional Siglo XXI	Mexico	Ciudad De México
Mexico	UMAE Hospital de Gineco-Obstetricia No.3 "Dr. Víctor Manuel Espinoza de los Reyes Sánchez" CMN La Raza.	Mexico City
Mexico	UMAE Hospital de Especialidades CMN "Gral. de Div. Manuel Ávila Camacho"	Puebla

Sponsors (1)

Lead Sponsor	Collaborator
Coordinación de Investigación en Salud, Mexico

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Use of emergency services	Change from baseline in the emergency room visits, which will be measured by the number of the emergency room visits during the previous month	At 1, 3, 6 and 9 months after intervention commencement
Other	Use of the responsive ePRO App in the intervention group	Frequency of the responsive ePRO App use (site visits by IP address) and completion of a weekly report of symptoms and supportive care needs on the responsive digital App.	At 1, 3 and 6 months after intervention commencement
Other	Unscheduled hospitalizations	Change from baseline in the unscheduled hospitalizations, which will be measured by the number of unscheduled hospitalizations in the previous month	At 1, 3, 6 and 9 months after intervention commencement
Other	Perceived usability of the responsive ePRO App in the intervention group	Perceived usability will be measured by mHealth Application Usability Questionnaire [ ] translated into Spanish with content validation completed by the study expert group.	At 1, 3 and 6 months after intervention commencement
Primary	Health systems and information supportive care needs	Change from baseline in health systems and information supportive care needs at 1, 3, 6 and 9 months after the intervention commencement, which will be measured with the Supportive Care Needs Survey Short Form-34 (SCNS SF-34) questionnaire validated in Mexico.	At 1, 3, 6 and 9 months after intervention commencement
Secondary	Global quality of life	Change from baseline in Global quality of life at 1, 3, 6 and 9 months after the intervention commencement, which will be measured with the EORTC (European Organization for Research and Treatment of Cancer) QLQ-C30 questionnaire validated in Mexico	At 1, 3, 6 and 9 months after intervention commencement
Secondary	Breast symptoms	Change from baseline in breast symptoms at 1, 3, 6 and 9 months after the intervention commencement, which will be measured with the breast symptoms scale of the EORTC QLQ-BR23 questionnaire validated in Mexico.	At 1, 3, 6 and 9 months after intervention commencement